Show simple item record

dc.contributor.authorPuttananjaiah, M.H.
dc.contributor.authorDhale, M.A.
dc.contributor.authorGaonkar, V.
dc.contributor.authorKeni, S.
dc.date.accessioned2011-03-09T10:56:07Z
dc.date.available2011-03-09T10:56:07Z
dc.date.issued2011
dc.identifier.citationApplied Biochemistry and Biotechnology, vol.163(2); 2011; 215-222
dc.identifier.urihttp://drs.nio.org/drs/handle/2264/3812
dc.description.abstractAtherosclerosis is a chronic inflammatory disease of multiple etiologies. It is associated with the accumulation of oxidized lipids in arterial lesions leading to coronary heart disease. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (commonly known as statins) are widely used in cardiovascular disease prevention to lower the cholesterol. The antioxidant activity of HMG-CoA reductase inhibitors was studied by lipid peroxidation inhibition assay, DPPH, and hydroxyl radical scavenging-activity methods. The lovastatin (93%) and simvastatin (96%) showed significant action of lipid peroxidation inhibition compared to other HMG-CoA reductase inhibitors. The DPPH radical and hydroxyl radical scavenging activity of simvastatin was 38% and 33%, respectively. The oxidative modification of serum lipid due to reactive oxygen species causes atherosclerosis. This study revealed the importance of lovastatin and simvastatin to prevent oxidative stress-related cardiovascular diseases
dc.language.isoen
dc.publisherSpringer
dc.rightsAn edited version of this paper was published by Springer. This paper is for R & D purpose and Copyright [2011] Springer.
dc.subjectAntioxidant
dc.subjectLipid peroxidation
dc.subjectHydroxyl radical
dc.subjectAtherosclerosis
dc.titleStatins: 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity
dc.typeJournal Article


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record